PGHL
Procter & Gamble Health Limited (PGHL) Stock Analysis
Procter and Gamble Health Limited markets over-the-counter and prescription brands including Vicks and Neurobion in India. It focuses on vitamins, cold remedies, and specialty pharma products. The company is the health-focused P&G arm in India. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹5,200.00
-0.10% 1W | -16.20% 52W
Market Cap
8.6k CR
P/E Ratio
24.2
52W High
₹6975
52W Low
₹4707
Div. Yield
3.01%
Beta
0.2
50 DMA
₹5621.6
200 DMA
₹5585.2
Profit Margin
24.9%
Inst. Own.
14.8%
🔥 APPROACHING RESISTANCE
📉 CONSOLIDATING DOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 301 | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 | 374 | 370 | 364 |
| Expenses | 256 | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 | 263 | 235 | 264 |
| Operating Profit | 45 | 89 | 102 | 67 | 48 | 114 | 123 | 81 | 90 | 120 | 110 | 136 | 100 |
| OPM % | 15% | 29% | 33% | 27% | 17% | 36% | 40% | 26% | 27% | 37% | 30% | 37% | 27% |
| Other Income | 5 | 6 | 5 | 2 | -18 | 3 | 4 | 3 | 4 | 5 | 4 | 4 | 36 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 | 6 | 6 | 6 |
| Profit before tax | 44 | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 | 109 | 133 | 129 |
| Tax % | 32% | 26% | 28% | 26% | 26% | 26% | 25% | 22% | 25% | 26% | 29% | 29% | 26% |
| Net Profit | 30 | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 | 78 | 95 | 96 |
| EPS in Rs | 17.96 | 39.50 | 43.42 | 28.05 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 | 46.74 | 56.99 | 57.92 |
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 202018m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 20259m | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 940 | 993 | 698 | 849 | 927 | 1,356 | 1,009 | 1,114 | 1,230 | 1,151 | 934 | 1,408 | 1,433 |
| Expenses | 855 | 877 | 621 | 701 | 723 | 1,037 | 762 | 846 | 905 | 845 | 616 | 949 | 967 |
| Operating Profit | 85 | 116 | 77 | 148 | 204 | 319 | 246 | 268 | 325 | 307 | 319 | 459 | 466 |
| OPM % | 9% | 12% | 11% | 17% | 22% | 24% | 24% | 24% | 26% | 27% | 34% | 33% | 33% |
| Other Income | 22 | 24 | 74 | 768 | 48 | 66 | 18 | 13 | 18 | -5 | 10 | 15 | 49 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 |
| Depreciation | 23 | 25 | 19 | 21 | 17 | 29 | 30 | 27 | 28 | 27 | 17 | 24 | 24 |
| Profit before tax | 83 | 115 | 132 | 895 | 234 | 355 | 233 | 253 | 314 | 273 | 312 | 450 | 490 |
| Tax % | 36% | 31% | 29% | 6% | 32% | 28% | 24% | 24% | 27% | 26% | 25% | 27% | |
| Net Profit | 54 | 79 | 94 | 839 | 159 | 254 | 177 | 193 | 229 | 201 | 234 | 327 | 357 |
| EPS in Rs | 32.27 | 47.67 | 56.57 | 505.27 | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 141.22 | 196.94 | 214.99 |
| Dividend Payout % | 23% | 23% | 27% | 87% | 0% | 150% | 122% | 45% | 69% | 215% | 89% | 104% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 8.0% | 1.0% | 4.0% |
| Profit CAGR | 19.0% | 5.0% | 20.0% |
Shareholding Pattern
Promoters51.82%
FIIs6.99%
DIIs14.15%
Public27.03%
Promoters51.82%
FIIs7.24%
DIIs13.90%
Public27.05%
Promoters51.82%
FIIs6.97%
DIIs13.84%
Public27.37%
Promoters51.82%
FIIs6.20%
DIIs13.67%
Public28.30%
Promoters51.82%
FIIs6.33%
DIIs12.44%
Public29.41%
Promoters51.82%
FIIs6.72%
DIIs12.31%
Public29.14%
Promoters51.82%
FIIs6.24%
DIIs13.72%
Public28.22%
Promoters51.82%
FIIs6.86%
DIIs14.21%
Public27.11%
Promoters51.82%
FIIs6.20%
DIIs13.67%
Public28.30%
Promoters51.82%
FIIs6.33%
DIIs12.44%
Public29.41%
PGHL
Holdings Analysis
Key strengths & risk signals
71
Overall
77
Fundamental
66
Technical
Risks (3)
WEAK POSITION! Current price (5200.0) is below both moving averages.
WEAK YEAR! Stock declined 16.2% in the last year.
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.1% (1 week), 4.8% (1 month), 23.5% (3 months).
Strengths (4)
FAIRLY VALUED! PEG of 1.25 indicates reasonable valuation.
BULLISH TREND! 50-day average (5621.6) is above 200-day average (5585.2) - positive signal.
BULLISH SENTIMENT! In last 30 days: 9 up days, 20 down days. Avg volume on up days: 18,410 vs down days: 8,836. Ratio: 2.08x
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
Fundamental & Technical Analysis
71Overall
77Fundamental
66Technical
Fundamental Breakdown
Growth Quality
21/30
Revenue CAGR: 8.2% (MODERATE, 8/15). Profit CAGR: 19.3% (VERY GOOD, 13/15).
Profit Margin
8/10
EXCELLENT EFFICIENCY! 24.9% profit margin - company keeps strong profits.
PEG Valuation
9/10
FAIRLY VALUED! PEG of 1.25 indicates reasonable valuation.
Dividend Yield
7/10
GOOD DIVIDEND! 3.01% yield - decent income potential.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 28.74% public ownership - balanced ownership structure.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
10/10
BULLISH TREND! 50-day average (5621.6) is above 200-day average (5585.2) - positive signal.
Price Position
2/10
WEAK POSITION! Current price (5200.0) is below both moving averages.
Trend Pattern
10/20
Current trend: CONSOLIDATING DOWN
52W Performance
2/10
WEAK YEAR! Stock declined 16.2% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 9 up days, 20 down days. Avg volume on up days: 18,410 vs down days: 8,836. Ratio: 2.08x
RSI
4/5
APPROACHING OVERSOLD! RSI at 37.9 - watch for reversal.
52W Range
2/5
LOWER HALF! Trading at 21.7% of 52W range - weakness visible.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.1% (1 week), 4.8% (1 month), 23.5% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PGHL | ₹5,200.00 | 24.2 | 24.9% | 8.2% | 19.3% | -16.2% | 71 | CONSOLIDATING DOWN | +45.3% | +1.7% | +7.4% | -1.8% |
| SUVEN | ₹303.60 | – | – | -19.3% | – | +49.1% | 55 | BREAKDOWN | +147.8% | +179.8% | +89.5% | +140.0% |
| SEQUENT | ₹201.20 | 123.4 | 2.5% | 3.1% | -18.9% | +26.2% | 55 | CONSOLIDATION | -13.9% | +161.2% | +10.9% | +102.5% |
| AARTIPHARM | ₹873.60 | 37.2 | 10.4% | -2.6% | -3.3% | +1.3% | 59 | CONSOLIDATING UP | +65.4% | +24.5% | +38.7% | -8.0% |
| STAR | ₹1,045.20 | 15.7 | 12.3% | 8.7% | – | +34.5% | 64 | BREAKDOWN | +57.5% | +23.6% | +13.0% | -4.4% |
| VIYASH | ₹226.00 | 55.3 | 5.9% | 33.3% | – | +15.1% | 60 | BOUNCE FROM SUPPORT | +107.2% | +26.5% | +19.6% | +2.9% |
| BLISSGVS | ₹652.00 | 51.7 | 13.5% | 7.2% | 22.1% | +334.4% | 73 | BREAKDOWN | +16.5% | +40.7% | +37.6% | +11.1% |
| MOREPENLAB | ₹123.90 | 48.4 | 7.2% | 8.4% | 34.9% | +161.2% | 72 | BREAKDOWN | +427.1% | +259.2% | +34.1% | +17.6% |
Data from TradeAlone · Updated daily
